Ardigen at Biomarker & IO World Congress 2018

Topic:

Between June 11th and 13th our representation attended the 14th Annual Biomarkers & Immuno-Oncology World Congress in Boston, one of the top world conferences about biomarker discovery and translational science for cancer treatment.

During the Congress, we had the opportunity to listen and interact with world top specialists in the field. We discussed talks and posters and gathered cutting-edge knowledge paying special attention to biomarkers for patient stratification, clinical trials design and strategies for rational treatment combination. During the poster sessions, we presented the latest results of our novel approach to translational science for immuno-oncology, catching the attention of various attendees.

Among the inspiring topics, we were able to hear about the latest results in biomarker detection and synergistic combination, liquid biopsy, and neoepitope research.

You might be also interested in:

Accelerating biomarker discovery through omic data integration into drug screens
Accelerating biomarker discovery through omic data integration
Two scientists observing AI-driven cell analysis on a digital screen, representing decision-making in biotech innovation.
Build or Buy? Strategic Considerations for Biotech Companies Implementing AI Solutions
biotech US market
AI in biotech: What the US market got right (and what it’s still learning)
From Data Chaos to Drug Discovery – Ardigen Talk at NextGen Omics Conference

Contact

Ready to transform drug discovery?

Discover how one of the top AI CROs in the world, can be your trusted partner in revolutionizing drug discovery through AI.

Contact us today to learn more about our tailored solutions for empowering your drug development journey.

Send us a message and we will contact you back within 48 hours.

Newsletter

Become an insider

Be the first to know about Ardigen’s latest news and get access to our publications, webinars and more!